11 Best Performing NASDAQ Stocks So Far in 2025

Page 10 of 10

1. Chimerix Inc. (NASDAQ:CMRX)

Number of Hedge Fund Holders: 17

Average Upside Potential as of March 31: 131.01%

Chimerix Inc. (NASDAQ:CMRX) is a biopharmaceutical company that develops medicines to improve and extend the lives of patients with rare and deadly diseases. One of its products includes the ONC201, which is a program in a Phase 3 clinical trial for patients with H3 K27M-mutant diffuse glioma, as well as in a Phase 2 clinical trial for the treatment of rare neuroendocrine tumors.

In Q4 2024, R&D expenses at the company increased to $17.7 million, which was year-over-year higher than $15.6 million from 2023. Currently, the company is targeting FDA approval for its Dordaviprone treatment for rare and aggressive brain cancer. Dordaviprone has received the Rare Pediatric Disease Designation, which is FDA status for accelerating the development of treatments for rare diseases in children.

Dordaviprone also has the Fast-Track Designation in the US and Orphan Drug Designation in the US, Europe, and Australia. The FDA has accepted the company’s application for a Priority Review, with a decision anticipated by August 18, 2025. If approved, this will be the first specific treatment for this type of cancer. The company is also preparing for Dordaviprone’s potential commercial launch.

While we acknowledge the growth potential of Chimerix Inc. (NASDAQ:CMRX), our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CMRX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 10 of 10